Development of the CRISPR/Cas9 System for Targeted Gene Disruption in Aspergillus fumigatus

Eukaryotic Cell
Kevin K FullerJay C Dunlap

Abstract

Low rates of homologous recombination have broadly encumbered genetic studies in the fungal pathogen Aspergillus fumigatus. The CRISPR/Cas9 system of bacteria has recently been developed for targeted mutagenesis of eukaryotic genomes with high efficiency and, importantly, through a mechanism independent of homologous repair machinery. As this new technology has not been developed for use in A. fumigatus, we sought to test its feasibility for targeted gene disruption in this organism. As a proof of principle, we first demonstrated that CRISPR/Cas9 can indeed be used for high-efficiency (25 to 53%) targeting of the A. fumigatus polyketide synthase gene (pksP), as evidenced by the generation of colorless (albino) mutants harboring the expected genomic alteration. We further demonstrated that the constitutive expression of the Cas9 nuclease by itself is not deleterious to A. fumigatus growth or virulence, thus making the CRISPR system compatible with studies involved in pathogenesis. Taken together, these data demonstrate that CRISPR can be utilized for loss-of-function studies in A. fumigatus and has the potential to bolster the genetic toolbox for this important pathogen.

References

Mar 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·M M YeltonW E Timberlake
Oct 1, 1996·Infection and Immunity·C D'EnfertJ P Latge
Jan 15, 1997·Nucleic Acids Research·K R OldenburgC Paddon
Aug 1, 1998·The Journal of Antimicrobial Chemotherapy·E K ManavathuP H Chandrasekar
Jan 18, 2005·Clinical Microbiology Reviews·Nina Singh, David L Paterson
Oct 20, 2006·Medical Mycology·Judith C Rhodes
Jan 24, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Arlo UptonKieren A Marr
Feb 3, 2007·Current Genetics·Christine HenryJean-Paul Latgé
Sep 18, 2007·Eukaryotic Cell·A George SmulianGeorge S Deepe
Jun 27, 2008·Current Opinion in Microbiology·David S Askew
May 1, 2009·The New England Journal of Medicine·Brahm H Segal
Jan 9, 2010·Science·Philippe Horvath, Rodolphe Barrangou
Feb 14, 2012·Methods in Molecular Biology·Fabrice N GravelatDonald C Sheppard
Feb 18, 2012·Nature·Blake WiedenheftJennifer A Doudna
Jun 30, 2012·Science·Martin JinekEmmanuelle Charpentier
Jan 5, 2013·Science·Le CongFeng Zhang
Jan 31, 2013·Nature Biotechnology·Wenyan JiangLuciano A Marraffini
Mar 6, 2013·Nucleic Acids Research·James E DiCarloGeorge M Church
Apr 3, 2013·Cell Research·Bin ShenXingxu Huang
Aug 10, 2013·Nature Biotechnology·Dali LiMingyao Liu
Aug 10, 2013·Nature Biotechnology·Qiwei ShanCaixia Gao
May 7, 2015·Biotechnology and Bioengineering·Ravichandra BachuLawrence A Chasin
Jul 16, 2015·PloS One·Christina S NødvigUffe H Mortensen

❮ Previous
Next ❯

Citations

Feb 18, 2016·Omics : a Journal of Integrative Biology·Luka CulibrkScott J Tebbutt
Jan 18, 2016·Fungal Genetics and Biology : FG & B·Theo A J van der Lee, Marnix H Medema
Feb 7, 2016·FEMS Microbiology Letters·Somayeh EnayatiVahid Khalaj
Dec 25, 2015·Fungal Genetics and Biology : FG & B·Chi ZhangLing Lu
Nov 10, 2015·Trends in Microbiology·Timothy C CairnsKen Haynes
Mar 19, 2016·Journal of Cellular Physiology·Jessica M WalterAndrew A Horwitz
Apr 14, 2016·ACS Synthetic Biology·Carsten PohlYvonne Nygård
Sep 10, 2016·ACS Synthetic Biology·Jakob WeberAxel A Brakhage
Oct 7, 2016·PloS One·Samantha D M ArrasJames A Fraser
Oct 22, 2016·Scientific Reports·Ludovic EnklerFabrice Jossinet
Nov 5, 2016·Medical Mycology·Sven Krappmann
Nov 20, 2016·Cellular Microbiology·M DoerflingerM J Herold
Apr 9, 2017·Applied Microbiology and Biotechnology·Ashraf S A El-SayedGul Shad Ali
May 28, 2017·Research in Microbiology·Huaxiang DengYujie Cai
Nov 2, 2017·Expert Review of Anti-infective Therapy·Marta TrevisanLuisa Barzon
Jun 20, 2018·Antimicrobial Agents and Chemotherapy·Takashi UmeyamaYoshitsugu Miyazaki
Mar 21, 2017·MSphere·Manning Y Huang, Aaron P Mitchell
Oct 25, 2017·Nature Microbiology·Rebecca S ShapiroJames J Collins
Jan 17, 2020·PLoS Pathogens·Florent MorioGeraldine Butler
Feb 28, 2019·International Microbiology : the Official Journal of the Spanish Society for Microbiology·Oier Etxebeste, Eduardo A Espeso
Nov 7, 2019·Current Genetics·Antara BarmanSupriyo Chakraborty
Nov 15, 2019·Clinical Microbiology Reviews·Jean-Paul Latgé, Georgios Chamilos
Jul 25, 2017·Current Microbiology·Prakriti Sharma Ghimire, Cheng Jin
Dec 24, 2018·Current Clinical Microbiology Reports·Alexis GarciaSoo Chan Lee
Dec 29, 2019·Scientific Reports·Massimo FerraraGiuseppina Mulè
May 30, 2020·International Journal of Molecular Sciences·Sandugash IbragimovaTamás Papp
Apr 16, 2020·Frontiers in Bioengineering and Biotechnology·Yu-Ke CenYu-Guo Zheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

CRISPR in Cancer

CRISPR-Cas system enables the editing of genes to create or correct mutations. Given that genome instability and mutation is one of the hallmarks of cancer, the CRISPR-Cas system is being explored to genetically alter and eliminate cancer cells. Here is the latest research.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.